Bruker

BRKR · NASDAQ

$55.93+$0.56 (+1.01%)TodayMarket closed · Oct 20, 7:30 PM ET

Prev close $55.37

BRKR analyst rating

HoldConsensus of 15 analysts over the last 12 months. 47% rate it a buy.

Strong buy0
Buy7
Hold7
Underperform0
Sell1

12-month price target · 15 analysts

Average $61.18 (+9.4% upside)

Low: $50.50
Now: $55.93
High: $73.50

Upgrades and downgrades

The latest rating actions, newest first

BRKR analyst upgrades, downgrades and rating actions
Firm	Date	Action	Rating	Price target	Hit rate
JP Morgan	Oct 14, 2026	Downgrade	Overweight → Neutral	$60.00	71%
TD Cowen	Oct 13, 2026	Maintains	Hold	$60.00 → $62.00	100%
Barclays	Oct 7, 2026	Maintains	Overweight	$58.00 → $70.00	54%
Guggenheim	Oct 1, 2026	Maintains	Buy	$70.00 → $72.00	66%
Leerink Partners	Sep 29, 2026	Maintains	Outperform	$60.00 → $80.00	51%
UBS	Sep 9, 2026	Maintains	Neutral	$45.00 → $65.00	59%
Citigroup	Aug 5, 2026	Maintains	Neutral	$60.00 → $53.00	75%
Citigroup	Jul 8, 2026	Maintains	Neutral	$44.00 → $60.00	55%
Leerink Partners	Jul 7, 2026	Maintains	Outperform	$60.00 → $70.00	51%
Guggenheim	Jun 29, 2026	Maintains	Buy	$50.00 → $70.00	66%

The case for and against

Updated Oct 22, 2025

Bull case

Bruker Corp is forecasting adjusted earnings per share (EPS) growth between 0% to 3% as reported, or 5% to 8% on a constant currency basis, indicating a resilience in profitability despite a downward revision from earlier expectations. The company reported an improvement in adjusted gross margins by 10 basis points to 51.3%, highlighting effective cost management and operational efficiency. Additionally, management anticipates a recovery in fiscal year 2026, post Tariff and Administrative & General (A&G) impacts, which supports a positive outlook for future growth.

Bear case

Bruker Corp has lowered its operating margin expectations for FY25 to flat, a significant drop from a prior forecast of an increase of 140 basis points, reflecting concerns about profitability. Additionally, management anticipates a decline in organic revenue for the second quarter due to softer conditions in the U.S. and China, along with delays in U.S.-produced revenue. Furthermore, the company's 2025 outlook for organic growth has been reduced to a range of 0% to 2%, falling short of Street expectations and indicating potential stagnation in core operations.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.